hVIVO achieves record first-half revenue as it expands with new Canary Whart headquarters

(8:14)

hVIVO achieves record revenue and initiates dividend policy following successful year

(8:58)

hVIVO CEO on record 2024 revenue and strategic CRS acquisition

(10:34)

hVIVO PLC - Company Presentation

(59:50)

hVIVO Year in Review 2024

(3:44)

hVIVO CEO discusses record H1 revenue and strategic expansion

(8:17)

hVIVO signs £11.5M RSV trial contract; expands services at new facility

(6:12)

Goodbye, Photoshop! Evoto saves me HOURS of editing

(10:35)

Growth Strategy (Expansion Strategy) Unit-6 Part-1 Class-14 (Strategy) Management

(10:14)

hVIVO's Mo Khan on the company’s breakthrough year

(10:48)

Open Orphan's Cathal Friel on the 'large opportunity' for hVIVO subsidiary malaria study

(3:1econd)

SageTech Medical device can reduce \

(5:18)

Soma Gold announces record monthly gold production at El Bagre mine for January

(3:46)

Open Orphan PLC on hVIVO signing its first phase 2 field study contract

(5:55)

Open Orphan's CEO on hVIVO's first ever Phase II field study site study awarded

(5:43)

FluCamp Clinical Trials by hVIVO

(1:7)

hVIVO Canary Wharf Facilities - Adam French

(4:8)

hVIVO secures RSV trial deal with Inhalon Pharma in the US

(7:49)

hVIVO, Solvonis Therapeutics, Genel Energy, Active Energy, Pantheon Intl - Small Cap Snapshot

(1:34)

hVIVO Careers - Fueling Scientific Research

(2:26)

hVIVO announces \

(7:6)

Lab Accreditation Awarded to hVIVO

(2:45)

hVIVO Asian growth strategy bearing fruit with second 2023 contract win

(4:7)

hVIVO to Develop hMPV Human Challenge Model

(5:36)

hVIVO Omicron Human Challenge Model

(7:14)

Poolbeg Pharma chair discusses shift to executive role; hVIVO share sale

(6:58)

Q\u0026A with hVIVO’s Mo Khan

(8:3)

hVIVO announces record financial performance for 2023; projects strong future growth

(8:)

hVIVO hail data on phase 2a study published in New England Journal of Medicine

(4:59)